The optimal dual antiplatelet therapy strategy, including the ideal agent, combination, or treatment duration for patients with coronary artery disease undergoing PCI, remains a subject of active debate.
What is the optimal dual antiplatelet therapy strategy (agent, combination, or duration) in patients with coronary artery disease undergoing PCI?
This review summarizes the evolution of dual antiplatelet therapy strategies in patients with coronary artery disease undergoing PCI, highlighting ongoing debates regarding optimal agents, combinations, and durations.
Abstract Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor has been the mainstay of therapy for acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) following percutaneous coronary intervention (PCI) for more than two decades. Over this period, numerous trials have evaluated different antiplatelet strategies, initially focusing on more effective and prolonged regimens, and more recently on decreasing the intensity or duration of DAPT. Despite a wealth of accumulated evidence, the optimal antiplatelet strategy – including the ideal agent, combination, or treatment duration - remains a subject of active debate. This review summarizes the evolution of antiplatelet therapy, with particular emphasis on randomized controlled trials of DAPT in patients with ACS or CCS undergoing PCI.
A scientific article on the evolving landscape of DAPT in coronary artery disease, highlighted by the EAPC, is prompting debate on optimal antiplatelet strategies.
Simonsson et al. (Tue,) conducted a review in Coronary Artery Disease. Dual antiplatelet therapy was evaluated. The optimal dual antiplatelet therapy strategy, including the ideal agent, combination, or treatment duration for patients with coronary artery disease undergoing PCI, remains a subject of active debate.